ORMP Stock Overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.
Oramed Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.64|
|52 Week High||US$17.51|
|52 Week Low||US$3.59|
|1 Month Change||30.51%|
|3 Month Change||1.41%|
|1 Year Change||-47.22%|
|3 Year Change||62.41%|
|5 Year Change||-0.69%|
|Change since IPO||4,651.80%|
Recent News & Updates
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?Jun 12
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In GrowthFeb 23
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn SituationNov 02
We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO CompensationAug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth PlansJul 21
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth PlansApr 06
The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About ItFeb 12
Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay MattersJan 08
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business GrowthDec 04
|ORMP||US Pharmaceuticals||US Market|
Return vs Industry: ORMP underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.
Return vs Market: ORMP underperformed the US Market which returned -21.2% over the past year.
|ORMP Average Weekly Movement||10.3%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ORMP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ORMP's weekly volatility (10%) has been stable over the past year.
About the Company
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.
Oramed Pharmaceuticals Inc. Fundamentals Summary
|ORMP fundamental statistics|
Is ORMP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ORMP income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.18|
|Net Profit Margin||-1,706.42%|
How did ORMP perform over the long term?See historical performance and comparison